Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Up – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $18.99, but opened at $20.49. Ascentage Pharma Group International shares last traded at $20.4250, with a volume of 1,047 shares changing hands.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on AAPG. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Deutsche Bank Aktiengesellschaft began coverage on shares of Ascentage Pharma Group International in a report on Friday, April 24th. They set a “buy” rating and a $40.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Monday, April 13th. Two investment analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. Based on data from MarketBeat, Ascentage Pharma Group International currently has an average rating of “Buy” and a consensus price target of $46.67.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The company’s fifty day moving average is $23.59 and its 200-day moving average is $26.34.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The business had revenue of $24.72 million for the quarter. As a group, equities analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Hedge Funds Weigh In On Ascentage Pharma Group International

A number of institutional investors and hedge funds have recently modified their holdings of AAPG. XY Capital Ltd boosted its stake in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the last quarter. UBS Group AG boosted its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International in the 2nd quarter worth $391,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth $383,000. Finally, ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth $204,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.